Abstract 2104
Background
Tyrosine kinase inhibitor-induced hypothyroidism is associated with favorable survival in patients with various cancers. We aimed to investigate the incidence of regorafenib-induced hypothyroidism and assess its prognostic value in patients with metastatic or unresectable colorectal cancer (CRC) receiving regorafenib.
Methods
This study included 68 patients with metastatic or unresectable CRC refractory to standard therapies from Asan Medical Center between 2014 and 2016. Regorafenib (160 mg/day on days 1–21, following a 7-day break) was administered.
Results
The median patient age was 58 (range, 26–72) years, and 61.8% of patients were male. Among the 68 patients, 50 (73.5%) showed hypothyroidism [subclinical hypothyroidism in 39 (57.4%) and symptomatic hypothyroidism in 11 (16.2%)]. Thyroid hormone replacement relieved fatigue, and the thyroid stimulating hormone level stabilized in patients with symptomatic hypothyroidism. Overall, the objective response rate (ORR) and disease control rate (DCR) were 7.4% and 70.6%, respectively, and were significantly higher in patients with symptomatic or subclinical hypothyroidism than in those with a euthyroid status (ORR: 27.3% vs. 5.1% vs. 0.0%, P = 0.001; DCR: 100% vs. 76.9% vs. 38.9%, P = 0.001). Median progression-free survival (PFS) and overall survival (OS) were longer in patients with symptomatic hypothyroidism than in those with subclinical hypothyroidism (median PFS: 9.1 vs. 3.8 months, P = 0.018; median OS: 19.2 vs. 9.4 months, P = 0.012) or those with a euthyroid status (median PFS: 9.1 vs. 1.8 months, P < 0.001; median OS: 19.2 vs. 4.7 months, P = 0.001). The occurrence of symptomatic hypothyroidism was a significant protective factor for PFS [hazard ratio (HR)=0.37, P = 0.006] and OS (HR = 0.35, P = 0.007).
Conclusions
As regorafenib-induced hypothyroidism occurs frequently and is associated with better survival in patients with metastatic CRC receiving regorafenib, active monitoring of the thyroid function status is necessary during regorafenib treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3278 - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma
Presenter: Luis Manso
Session: Poster Display session 2
Resources:
Abstract
4906 - Tumor-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A restrospective study
Presenter: Sara Giovannoni
Session: Poster Display session 2
Resources:
Abstract
3919 - Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer.
Presenter: Periklis Foukas
Session: Poster Display session 2
Resources:
Abstract
5139 - Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: a MITO24 retrospective study
Presenter: Alberto Farolfi
Session: Poster Display session 2
Resources:
Abstract
4212 - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)
Presenter: Marc Cucurull Salamero
Session: Poster Display session 2
Resources:
Abstract
5123 - TP53 Hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer
Presenter: Marica Garziera
Session: Poster Display session 2
Resources:
Abstract
3795 - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Presenter: Dominique Berton-Rigaud
Session: Poster Display session 2
Resources:
Abstract
2359 - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
Presenter: Alexandra Tyulyandina
Session: Poster Display session 2
Resources:
Abstract
3619 - Baseline IPI (Immune Prognostic Index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI).
Presenter: Felix Blanc-Durand
Session: Poster Display session 2
Resources:
Abstract
3474 - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive inmmunotherapy in ovarian cancer
Presenter: Diego Salas-Benito
Session: Poster Display session 2
Resources:
Abstract